Hartaj Singh is Managing Director and Senior Analyst, Biotechnology at Oppenheimer & Co. Inc. Earlier, Mr. Singh was Managing Director and Senior Biotechnology Analyst at BTIG Securities. He began his sellside career at Lehman Brothers and subsequently moved to the buy side covering biotechnology at Visium Asset Management and Tecumseh Partners. He began his career as a clinical trial project manager for ClinTrials Research and also worked as a strategic analysis manager for Johnson & Johnson, both of which give him experience in clinical trial design. Mr. Singh has a B.A. in biology from Case Western Reserve University and also did graduate work in computational neurobiology. He received an MBA from Duke University’s Fuqua School of Business.
Three Large-Cap Biotechs That Stand Out in an Uncertain Market
April 06, 2023
Sizing Up Risk Across the Biotech Cap Spectrum
August 18, 2022
Midcap and Small-Cap Biopharma Opportunities a Better Way to Go in 2021
September 30, 2020
The First Half of 2019 Expected to Be Rough for the Biotech Sector
March 15, 2019
Good Management Teams and Good Science are Creating Opportunities in Biotech
March 08, 2018
Biotech Space Lining Up for New Product Cycle
April 21, 2017
